Literature DB >> 18294397

The importance of left ventricular function for long-term outcome after primary percutaneous coronary intervention.

Pieter A van der Vleuten1, Saman Rasoul, Willem Huurnink, Iwan Cc van der Horst, Riemer Hja Slart, Stoffer Reiffers, Rudi A Dierckx, René A Tio, Jan Paul Ottervanger, Menko-Jan De Boer, Felix Zijlstra.   

Abstract

BACKGROUND: In the present study we sought to determine the long-term prognostic value of left ventricular ejection fraction (LVEF), assessed by planar radionuclide ventriculography (PRV), after ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PPCI).
METHODS: In total 925 patients underwent PRV for LVEF assessment after PPCI for myocardial infarction before discharge from the hospital. PRV was performed with a standard dose of 500 Mbq of 99mTc-pertechnetate. Average follow-up time was 2.5 years.
RESULTS: Mean (+/- SD) age was 60 +/- 12 years. Mean (+/- SD) LVEF was 45.7 +/- 12.2 %. 1 year survival was 97.3 % and 3 year survival was 94.2 %. Killip class, multi vessel-disease, previous cardiovascular events, peak creatin kinase and its MB fraction, age and LVEF proved to be univariate predictors of mortality. When entered in a forward conditional Cox regression model age and LVEF were independent predictors of 1 and 3 year mortality.
CONCLUSION: LVEF assessed by PRV is a powerful independent predictor of long term mortality after PPCI for STEMI.

Entities:  

Mesh:

Year:  2008        PMID: 18294397      PMCID: PMC2278125          DOI: 10.1186/1471-2261-8-4

Source DB:  PubMed          Journal:  BMC Cardiovasc Disord        ISSN: 1471-2261            Impact factor:   2.298


Background

The management of patients with an acute ST-elevation myocardial infarction (STEMI) has fundamentally changed over the last twenty years. In the eighties thrombolytic agents were introduced and more recently primary percutaneous coronary intervention (PPCI) has been shown to be even more effective [1,2]. In patients surviving the first days after PPCI, risk stratification is of great clinical relevance for the further (medical) management. Among others, global left ventricular function has always been viewed as an important prognostic factor after acute myocardial infarction. Earlier trials in large cohorts of STEMI-patients, treated with either thrombolytic agents or supportive care (no reperfusion-therapy), have confirmed this prognostic value for a period of six months after myocardial infarction [3-7]. Planar radionuclide ventriculography (PRV) is a well established and widely used technique for the assessment of left ventricular function. The technique is simple, robust and easy to perform [8-10]. PRV assesses LVEF by measurement of photon-activity of the bloodpool in the left ventricle in both the end-diastolic and end-systolic phase of the cardiac cycle. The aim of the present study was to evaluate the long term prognostic value of LVEF, assessed by routine PRV, in a large cohort of patients treated with PPCI for STEMI.

Methods

As part of two consecutive multicentre randomized controlled trials consecutive patients treated with PPCI for STEMI in two large hospitals in the Netherlands were entered in a registry [11,12]. The registry was opened in April 1998 and was closed in December 2004. The inclusion criteria differed in inclusion of all Killip classes in GIPS 1 [11] versus only Killip 1 in GIPS 2 [12]. Baseline characteristics such as medical history, cardiovascular risk factors, heart rate and blood pressure, delay-times and procedural parameters were recorded. For the present study data from the registries of two large hospitals in The Netherlands were used. Average follow-up time was 2.5 years. No patients were lost to follow-up. The present study was conducted in accordance with the declaration of Helsinki and was approved by the institutional review boards of both cooperating hospitals. PRV was performed in routine clinical practice before discharge from the hospital, between day 1 and day 11 after myocardial infarction. Four patients with atrial fibrillation were excluded. Measurements were performed using the multiple-gated equilibrium method with in vivo labelling of red blood cells with 99mTc pertechnetate, after pre-treatment with 1 mg. of stannous chloride. A γ-camera (General Electric, Milwaukee, WI, U.S.A.) was used. The camera head was positioned in the best septal LAO projection, typically with a caudal tilt of 5–10 degrees. R-wave triggering was performed in a 20% beat acceptance window with 2/3 forward and 1/3 backward framing per cardiac cycle, for 20 frames per R-R interval for a total of 6 minutes. LVEF was calculated using a Star View computer (General Electric, Wisconsin, USA) using the fully automatic PAGE program (version 2.3). The standard deviation of the difference between repeat measurements obtained by this technique is 1–2% [13].

Statistical analyses

Analyses were performed with the commercially available package SPSS version 12.0.1 (SPSS inc, Chicago, IL, USA). Continuous data of LVEF values were expressed as mean ± standard deviation (SD). Mortality rates were calculated according to the product-limit method. Further estimation of risk was performed using Cox proportional hazards models. Variables considered as potential predictors for multivariable modelling were selected by univariate analyses and were subsequently selected by stepwise forward selection, with entry and retention in the model set at a significance level of .05.

Results

PRV was not performed in 14 patients because they were too hemodynamically unstable. Furthermore 10 patients died before PRV could be performed. In total 925 patients underwent routine PRV. Clinical and angiographic characteristics are shown in Table 1. All patients underwent PPCI of the infarct related artery, which was successful in 87.2% (defined as TIMI 3 flow in combination with a myocardial blush grade ≥ 2). PRV was performed at a median of 2 days after PPCI (range 1 day – 11 days). Mean LVEF was 45.7 ± 12.2 % (interquartile-range: 37.0 % – 54.0 %).
Table 1

Baseline clinical and angiographic characteristics

Age, yrs (mean ± SD)59.8 ± 12.0
Male sex77.8
Body mass index, kg/m2 (mean ± SD)26.7 ± 3.8
History of MI9.9
History of PCI5.1
History of CABG2.8
History of stroke2.8
Diabetes mellitus9.7
Hypertension28.5
Hyperlipidemia22.1
Current smoker50.7
Positive family history42.3
Ischemia duration, min (mean ± SD)*205 ± 212
Killip class 195.9
Killip class 22.4
Killip class 31.3
Killip class 40.4
Anterior MI48.6
Multivessel disease51.4
TIMI 3 flow after PCI96.9
Successful reperfusion‡87.2
Intra-aortic balloon pump5.0
Mechanical ventilation0.5
Stent57.6
Glycoprotein IIb/IIIa receptor blocker21.2
Max CK, U/l (mean ± SD)2450 ± 2159
Max CK-MB, U/l (mean ± SD)248 ± 198

Data are displayed as percentage, unless otherwise indicated. *Ischemia duration denotes time between onset of symptoms and until PCI; ‡successful reperfusion denotes TIMI 3 flow and myocardial blush grade 2 or 3;

CABG = coronary artery bypass grafting

CK = creatin kinase

CK-MB = creatin kinase myoglobin binding

MI = myocardial infarction

PCI = percutaneous coronary intervention

SD = standard deviation

TIMI = thrombolysis in myocardial infarction

Baseline clinical and angiographic characteristics Data are displayed as percentage, unless otherwise indicated. *Ischemia duration denotes time between onset of symptoms and until PCI; ‡successful reperfusion denotes TIMI 3 flow and myocardial blush grade 2 or 3; CABG = coronary artery bypass grafting CK = creatin kinase CK-MB = creatin kinase myoglobin binding MI = myocardial infarction PCI = percutaneous coronary intervention SD = standard deviation TIMI = thrombolysis in myocardial infarction Follow-up was obtained for all 925 patients. All-cause mortality was 0.2 %, 0.9 %, 2.7 % and 5.8 % at 3 days, 30 days, 1 year and 3 years respectively. Three day mortality in the entire registry was 2.3 %. Kaplan Meier curves for all-cause mortality in the 925 patients who underwent PRV before discharge are shown in Figure 1. The unadjusted mortality rate increased exponentially with decreasing LVEF (Figure 2).
Figure 1

Kaplan-Meier curve of 925 patients who underwent planar radionuclide ventriculography after primary percutaneous coronary intervention for ST-elevation myocardial infarction. LVEF = Left Ventricular Ejection Fraction.

Figure 2

Adjusted 3 year mortality rate for patients who underwent planar radionuclide ventriculography after primary percutaneous coronary intervention for ST-elevation myocardial infarction, grouped by left ventricular ejection fraction.

Kaplan-Meier curve of 925 patients who underwent planar radionuclide ventriculography after primary percutaneous coronary intervention for ST-elevation myocardial infarction. LVEF = Left Ventricular Ejection Fraction. Adjusted 3 year mortality rate for patients who underwent planar radionuclide ventriculography after primary percutaneous coronary intervention for ST-elevation myocardial infarction, grouped by left ventricular ejection fraction. By univariate Cox proportional hazards analysis several baseline clinical characteristics and infarct related parameters were shown to be significant predictors of death. Significant predictors of both 1 year and 3 year mortality were age, history of MI, history of PCI, peak CK, peak CK-MB-fraction and LVEF. Killip class, multivessel disease and history of CABG were only significant univariate predictors of 3 year mortality. Details are shown in Table 2. Sex, history of stroke, diabetes, hypertension, hyperlipidemia, smoking habit, positive family history, infarct-duration, infarct location, TIMI flow after PPCI, myocardial blush grade, use of G2b3a inhibitors, use of intra-aortic balloon pump or mechanical ventilation were not significant predictors of mortality. When a forward conditional Cox proportional hazard model of only the factors age and LVEF was implemented, none of the other variables provided incremental prognostic value (Table 3).
Table 2

Predictors of 1 and 3 year mortality by univariate Cox proportional hazard analysis.

1 year mortality
CharacteristicsHazard ratio (95% CI)p
Age, per 10 years increase2.00 (1.35 – 2.97)0.001
Previous MI2.91 (1.16 – 7.28)0.023
Previous PCI9.58 (4.13 – 22.21)< 0.001
Max CK, per 500 U/l increase1.01 (1.00 – 1.02)0.050
Max CK-MB, per 50 U/l increase1.09 (1.01 – 1.18)0.039
LVEF, per 5 % decrease1.47 (1.25 – 1.73)< 0.001
3 year mortality
CharacteristicsHazard ratio (95% CI)p
Age, per 10 years increase1.63 (1.25 – 2.14)< 0.001
Previous MI2.19 (1.06 – 4.52)0.035
Previous PCI5.16 (2.50 – 10.7)< 0.001
Previous CABG3.27 (1.17 – 9.10)0.024
Multi-vessel disease1.50 (1.06 – 2.11)0.021
Killip class, per class increase1.73 (1.08 – 2.75)0.022
Max CK, per 500 U/l increase1.01 (1.00 – 1.02)0.040
Max CK-MB, per 50 U/l increase1.07 (1.01 – 1.14)0.020
LVEF, per 5 % decrease1.29 (1.15 – 1.46)< 0.001

CABG = coronary artery bypass grafting

CK = creatin kinase

CK-MB = creatin kinase myoglobin binding

LVEF = left ventricular ejection fraction

MI = myocardial infarction

PCI = percutaneous coronary intervention

Table 3

Predictors of 1 and 3 years mortality by forward conditional Cox proportional hazard analysis.

1 year mortality
CharacteristicsHazard ratio95% CIWald χ2p
Age, per 10 years2.011.33 – 3.0311.10.001
LVEF, per 5 % decreasing1.441.23 – 1.6920.4< 0.001
3 year mortality
CharacteristicsHazard ratio95% CIWald χ2p
Age, per 10 years1.641.25 – 2.1512.6< 0.001
LVEF, per 5 % decreasing1.281.14 – 1.4417.6< 0.001

LVEF = left ventricular ejection fraction

Predictors of 1 and 3 year mortality by univariate Cox proportional hazard analysis. CABG = coronary artery bypass grafting CK = creatin kinase CK-MB = creatin kinase myoglobin binding LVEF = left ventricular ejection fraction MI = myocardial infarction PCI = percutaneous coronary intervention Predictors of 1 and 3 years mortality by forward conditional Cox proportional hazard analysis. LVEF = left ventricular ejection fraction

Discussion

The present study shows that LVEF assessed shortly after PPCI for STEMI, is a powerful predictor of long term survival. Earlier studies, most designed to establish the value of various pharmacologic interventions after myocardial infarction, have shown the prognostic value of global left ventricular function, measured as LVEF, in terms of mortality and re-admission rates for heart failure [14-17]. However, the follow-up duration and patient selection differed from the present study. The event-rate was relatively low for a post-infarction cohort, with a 3 year mortality of only 5.8 %. The fact that this study looks at data from patients who underwent PRV on average 2 days after PPCI in the routine of daily clinical practice, in most cases just before discharge or transfer to another hospital, has systematically excluded patients who were too hemodynamically unstable to undergo PRV. For all analyses total mortality was used. It can be hypothesized that the relationship between LVEF and cause-specific mortality would be even stronger. The fact that the traditional risk-factors for coronary artery disease (sex, hypertension, diabetes, hyperlipidemia, smoking and family history) were not significant predictors of mortality may be explained by the fact that these risk-factors for the most part contributed to the occurrence of the index-MI itself and have only limited effect on the prognosis after the index-MI. In addition, a number of these risk-factors (hypertension, hyperlipidemia and smoking) is usually treated more aggressively after the index-MI. The fact that some infarct-treatment parameters, such as use of mechanical ventilation and use of IABP, were not significant predictors of mortality is most likely explained by the relatively low numbers in this cohort with a relatively low event-rate. Noteworthy is the relatively small difference in prognosis between the patient category with LVEF between 35 % and 55 % and the patient category with LVEF above 55 %, which is generally viewed as the lower limit of normal. In contrast, there was a large difference in survival between the patient category with LVEF between 35 % and 55 % and the patient category with LVEF below 35, which is the current cut-off point for implantable cardioverter defibrillator implementation (Figure 1). The data in the present study suggest that markers of infarct size, such as maximum creatin kinase myoglobin binding level, Killip class and previous myocardial damage from earlier events add up to a risk burden which is related to global left ventricular function. LVEF can therefore be viewed as a representative of the final common pathway of left ventricular damage when predicting long-term prognosis after PPCI. The fact that this LVEF-assessment can be performed just a few days after the index myocardial infarction facilitates simple and fast risk stratification after PPCI. Besides PRV, LVEF can be measured by a number of techniques, which all have their own specific advantages and limitations. For instance echocardiography can be performed easily and at low cost. However, the diagnostic accuracy is limited [18]. Nuclear techniques such as positron emission tomography and single photon emission computed tomography have better diagnostic accuracy, but are more labour intensive and are not available in every hospital. Recently, multi detector row computed tomography has been propagated as very fast and accurate technique for LVEF assessment [19]. However, besides ionising radiation, this technique also requires the use of intravenous nephrotoxic contrast agents. LVEF can even be assessed directly after PPCI by contrast ventriculography. Besides the obvious advantage of almost instant LVEF-assessment, the main drawbacks from this approach are the relatively high volume of nephrotoxic contrast, the limited accuracy and the fact that LVEF can be severely underestimated by myocardial stunning shortly after STEMI. Magnetic resonance imaging is regarded by many to be the gold standard for LVEF measurement [20]. Unfortunately, this technique is limited to patients without intra-corporal devices such as pacemakers and is not generally available for routine clinical patients.

Conclusion

In conclusion, LVEF assessed by PRV before discharge from the hospital is a powerful independent predictor of long term prognosis after PPCI for STEMI.

Abbreviations

CABG = Coronary artery bypass grafting, CK = Creatin kinase, CK-MB = Creatin kinase myocardial band, LVEF = Left ventricular ejection fraction, PCI = Percutaneous coronary intervention, PPCI = Primary percutaneous coronary intervention, PRV = Planar radionuclide ventriculography, SD = Standard deviation, STEMI = ST-elevation myocardial infarction, TIMI = Thrombolysis in myocardial infarction (study group).

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

PVV contributed in data-collection, data-analysis and drafting the manuscript. SR contributed in data-collection, data-analysis and drafting the manuscript. WH contributed in PRV acquisition in Zwolle and drafting the manuscript. ICH contributed in designing the study, data-analysis and drafting the manuscript. RHS contributed in PRV acquisition in Groningen and drafting the manuscript. SR contributed in designing the study, data-analysis and drafting the manuscript. RAD contributed in data-analysis and drafting the manuscript. RAT contributed in study-design, data-analysis and drafting the manuscript. JPO contributed in study-design and drafting the manuscript. MJB contributed in study-design and drafting the manuscript. FZ contributed in study-design, data-analysis and drafting the manuscript. All authors have read and approved the final version of the manuscript.

Pre-publication history

The pre-publication history for this paper can be accessed here:
  20 in total

1.  Effect of increased body mass index on accuracy of two-dimensional echocardiography for measurement of left ventricular volume, ejection fraction, and mass.

Authors:  M L Chuang; P G Danias; M F Riley; M G Hibberd; W J Manning; P S Douglas
Journal:  Am J Cardiol       Date:  2001-02-01       Impact factor: 2.778

2.  Radionuclide ventriculographic quantitation of left ventricular dimensions. Comparison to echocardiography.

Authors:  L D Madanay; M D Cerqueira; A F Jacobson; D Matsuoka; M Matsuda; J R Stratton
Journal:  Clin Nucl Med       Date:  1991-08       Impact factor: 7.794

3.  Value of noninvasive techniques for predicting early complications in patients with clinical class II acute myocardial infarction.

Authors:  D S Abrams; M R Starling; M H Crawford; R A O'Rourke
Journal:  J Am Coll Cardiol       Date:  1983-11       Impact factor: 24.094

4.  Mortality in patients with left ventricular ejection fraction </=30% after primary percutaneous coronary intervention for ST-elevation myocardial infarction.

Authors:  Jan Paul Ottervanger; Anand R Ramdat Misier; Jan-Henk E Dambrink; Menko-Jan de Boer; Jan C A Hoorntje; A T Marcel Gosselink; Harry Suryapranata; Stoffer Reiffers; Arnoud W J van 't Hof
Journal:  Am J Cardiol       Date:  2007-06-14       Impact factor: 2.778

5.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

6.  Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis. Results of the GISSI-2 data base. The Ad hoc Working Group of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-2 Data Base.

Authors:  A Volpi; C De Vita; M G Franzosi; E Geraci; A P Maggioni; F Mauri; E Negri; E Santoro; L Tavazzi; G Tognoni
Journal:  Circulation       Date:  1993-08       Impact factor: 29.690

7.  Cardiac function at rest and during exercise in normals and in patients with coronary heart disease: evaluation by radionuclide angiocardiography.

Authors:  S K Rerych; P M Scholz; G E Newman; D C Sabiston; R H Jones
Journal:  Ann Surg       Date:  1978-05       Impact factor: 12.969

8.  A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction.

Authors:  F Zijlstra; M J de Boer; J C Hoorntje; S Reiffers; J H Reiber; H Suryapranata
Journal:  N Engl J Med       Date:  1993-03-11       Impact factor: 91.245

Review 9.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

Authors:  Ellen C Keeley; Judith A Boura; Cindy L Grines
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

10.  Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial.

Authors:  Iwan C C van der Horst; Felix Zijlstra; Arnoud W J van 't Hof; Carine J M Doggen; Menko-Jan de Boer; Harry Suryapranata; Jan C A Hoorntje; Jan-Henk E Dambrink; Rijk O B Gans; Henk J G Bilo
Journal:  J Am Coll Cardiol       Date:  2003-09-03       Impact factor: 24.094

View more
  14 in total

1.  Evaluation of global left ventricular function assessment of non-fluorescent electromechanical endocardial mapping compared with biplane left ventricular contrast angiography.

Authors:  E-S Tan; P A Van der Vleuten; G A J Jessurun; R A Tio; F Zijlstra; I C Van Gelder
Journal:  Neth Heart J       Date:  2010-02       Impact factor: 2.380

2.  The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial.

Authors:  Vivian G Ng; Alexandra J Lansky; Stephanie Meller; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce Brodie; Ruchit Shah; Roxana Mehran; Gregg W Stone
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2013-10-03

3.  Additive prognostic value of left ventricular ejection fraction to the TIMI risk score for in-hospital and long-term mortality in patients with ST segment elevation myocardial infarction.

Authors:  Xue-Biao Wei; Yuan-Hui Liu; Peng-Cheng He; Lei Jiang; Ying-Ling Zhou; Ji-Yan Chen; Ning Tan; Dan-Qing Yu
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

4.  Single-Breath-Hold Evaluation of Cardiac Function with Use of Time-Resolved Parallel Cardiac Magnetic Resonance.

Authors:  Patrick Krumm; Jonas D Keuler; Stefanie Mangold; Tanja Zitzelsberger; Christer A Ruff; Bernhard D Klumpp; Petros Martirosian; Konstantin Nikolaou; Christof Burgstahler; Ulrich Kramer
Journal:  Tex Heart Inst J       Date:  2017-08-01

5.  Amelioration of persistent left ventricular function impairment through increased plasma ascorbate levels following myocardial infarction.

Authors:  Nicolás Valls; Juan G Gormaz; Rubén Aguayo; Jaime González; Roberto Brito; Daniel Hasson; Matías Libuy; Cristóbal Ramos; Rodrigo Carrasco; Juan C Prieto; Gastón Dussaillant; Ángel Puentes; Viviana Noriega; Ramón Rodrigo
Journal:  Redox Rep       Date:  2016-02-24       Impact factor: 4.412

6.  Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial.

Authors:  Stefanie Schulz; Julinda Mehilli; Gjin Ndrepepa; Franz Dotzer; Michael Dommasch; Sebastian Kufner; Kathrin A Birkmeier; Klaus Tiroch; Robert A Byrne; Albert Schömig; Adnan Kastrati
Journal:  Clin Res Cardiol       Date:  2011-03-08       Impact factor: 5.460

7.  Granulocyte colony-stimulating factor therapy for stem cell mobilization following anterior wall myocardial infarction: the CAPITAL STEM MI randomized trial.

Authors:  Benjamin Hibbert; Bradley Hayley; Robert S Beanlands; Michel Le May; Richard Davies; Derek So; Jean-François Marquis; Marino Labinaz; Michael Froeschl; Edward R O'Brien; Ian G Burwash; George A Wells; Ali Pourdjabbar; Trevor Simard; Harold Atkins; Christopher Glover
Journal:  CMAJ       Date:  2014-06-16       Impact factor: 8.262

8.  Semi-automatic assessment of global left ventricular function and left ventricular parameters with dual-source computed tomography: comparison with invasive angiography.

Authors:  Tanja Drosch; Ilias Tsiflikas; Harald Brodoefel; Martin Heuschmid; Anja Reimann; Christoph Thomas; Dominik Ketelsen; Diana Wurster; Stephen Schroeder; Christof Burgstahler
Journal:  Heart Vessels       Date:  2010-01-21       Impact factor: 2.037

9.  Prognostic impact of mean heart rate by Holter monitoring on long-term outcome in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.

Authors:  Gang Liu; Jian Shen; Yuan Yang; Xiang Li; Yuansong Zhu; Zhenxian Xiang; Hongbo Gan; Bi Huang; Suxin Luo
Journal:  Clin Res Cardiol       Date:  2021-02-06       Impact factor: 5.460

10.  Leukocyte telomere length and left ventricular function after acute ST-elevation myocardial infarction: data from the glycometabolic intervention as adjunct to primary coronary intervention in ST elevation myocardial infarction (GIPS-III) trial.

Authors:  Vincent G Haver; Minke H T Hartman; Irene Mateo Leach; Erik Lipsic; Chris P Lexis; Dirk J van Veldhuisen; Wiek H van Gilst; Iwan C van der Horst; Pim van der Harst
Journal:  Clin Res Cardiol       Date:  2015-04-04       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.